Anavex: Alzheimer's To Parkinson's Dementia

grayscale photography of person covering face

Photo by Danie Franco on Unsplash

Anavex Life Sciences (AVXL), is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, asserts Tom Bishop, editor of BI Research.


Its lead candidate, Anavex 2-73 (A2-73 or blarcamesine) is currently in a Phase 2b/3 clinical trial on Alzheimer’s. A2-73 is an orally available drug candidate that targets Sigma-1 and muscarinic receptors (rather than existing amyloid plaques), with a clean safety profile that shows promise to halt and/or possibly even reverse the course of Alzheimer’s if taken early.

A2-73 has also completed a successful Phase 2 clinical trial for Parkinson’s dementia. In addition, A2-73 has shown strong Phase 3 results for the treatment of Rett Syndrome with data from a pediatric trial due in H2. The consistency of clinical trial success to date in all three diseases, and with strong statistical significance, is a very encouraging sign here.

Following a huge gain in 2021 (after a big gain in 2020), the shares have given back 27% year-to-date as investors ride out a quiet stretch awaiting trial results from the all-important 506-patient Phase 2b/3 Alzheimer’s trial as well as the 84-patient Rett adolescent trial, both due in the second half of this year.

In the meantime Anavex will be meeting with the FDA to okay its Phase 3 Parkinson’s trials on dementia and movement as well as to see if data from the 2 adult Rett trials completed so far could justify an approval for adult Rett syndrome even before the adolescent indication. Anavex has $150 million in cash to accomplish this.

Meanwhile, based on consistently positive and significant results across numerous clinical research trials (every one so far), the shares remain a "buy" for believers.

Disclaimer: © 2022 MoneyShow.com, LLC. All Rights Reserved. 

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with
Michele Grant 2 years ago Member's comment

Nice simple article that hits most high points.  Just a few more points:
* The remaining ReTT trial is for 5 to 17 year olds, which I would call juvenile or pediatric instead of adolescent.
* The only current competitor for a ReTT treatment (Acadia) subjected many of their patients to vomiting & diarrhea, which is not a side effect of 2-73.  Additionally, 2-73 appears to be more efficacious based on top line results.
* Anavex's 509-person Alzheimer's trial is scheduled to finish before any other phase 3 trial registered with the FDA.
* The PDD OLE data set should be complete about the same time the phase 3 Alzheimer's data set is complete.